Increased Expression of LYNX1 in Ovarian Serous Cystadenocarcinoma Predicts Poor Prognosis.
Adaptor Proteins, Signal Transducing
/ metabolism
Aged
Biomarkers, Tumor
/ genetics
Cystadenocarcinoma, Serous
/ diagnosis
Female
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Genome, Human
Humans
Immune System
Kaplan-Meier Estimate
Middle Aged
Ovarian Neoplasms
/ diagnosis
Prognosis
Proportional Hazards Models
Survival Rate
Treatment Outcome
Journal
BioMed research international
ISSN: 2314-6141
Titre abrégé: Biomed Res Int
Pays: United States
ID NLM: 101600173
Informations de publication
Date de publication:
2020
2020
Historique:
received:
09
08
2020
revised:
15
11
2020
accepted:
16
11
2020
entrez:
10
12
2020
pubmed:
11
12
2020
medline:
9
6
2021
Statut:
epublish
Résumé
Few studies have reported the function of LYNX1 in ovarian cancer. We retrieved LYNX1 gene expression data and clinical information of 376 patients with ovarian cancer from The Cancer Genome Atlas (TCGA) project website. Wilcoxon signed-rank test and logistic regression were used to analyze the relationship between clinical pathologic features and LYNX1 expression. The Kaplan-Meier method was used to draw survival curves of patients, and Cox regression was used to calculate the relationship between LYNX1 expression and survival rate or the clinicopathological characteristics of the patients. Gene set enrichment analysis (GSEA) was performed, and the correlation between LYNX1 expression and cancer immune infiltrates was investigated via single sample gene set enrichment analysis (ssGSEA). High LYNX1 expression in ovarian serous cystadenocarcinoma (OVs) was associated with tumor residual disease (RD). In Kaplan-Meier survival analysis, patients with OVs who also displayed high LYNX1 expression had decreased overall survival (OS) and disease-specific survival (DSS) than those with low LYNX1 expression. Univariate analysis also supported that patients with high LYNX1 expression had lower OS than those with low LYNX1 expression. LYNX1 expression has the potential to be a prognostic molecular marker of poor survival in OVs.
Identifiants
pubmed: 33299855
doi: 10.1155/2020/1392674
pmc: PMC7710416
doi:
Substances chimiques
Adaptor Proteins, Signal Transducing
0
Biomarkers, Tumor
0
LYNX1 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1392674Informations de copyright
Copyright © 2020 Hui Liu et al.
Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest regarding the publication of this article.
Références
Neuron. 1999 May;23(1):105-14
pubmed: 10402197
Acta Biochim Biophys Sin (Shanghai). 2008 May;40(5):426-36
pubmed: 18465028
Lancet. 2014 Oct 11;384(9951):1376-88
pubmed: 24767708
Cancer Lett. 2015 Apr 1;359(1):117-26
pubmed: 25592043
Ginekol Pol. 2018;89(5):249-255
pubmed: 30084476
Curr Probl Cancer. 2019 Oct;43(5):450-460
pubmed: 30670303
Oncol Lett. 2018 Aug;16(2):1375-1382
pubmed: 30008813
Oncotarget. 2016 Mar 8;7(10):11165-93
pubmed: 26862846
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Gynecol Oncol. 2003 Jan;88(1 Pt 2):S149-51
pubmed: 12586108
Immunity. 2013 Oct 17;39(4):782-95
pubmed: 24138885
Mol Carcinog. 2018 Nov;57(11):1626-1639
pubmed: 30074282
J Neuroimmune Pharmacol. 2015 Sep;10(3):468-76
pubmed: 25870122
Methods Mol Biol. 2016;1418:111-41
pubmed: 27008012
Microsc Res Tech. 2002 Dec 15;59(6):503-8
pubmed: 12467026
J Invest Dermatol. 2006 Sep;126(9):1948-65
pubmed: 16912692
Biostatistics. 2007 Jan;8(1):118-27
pubmed: 16632515
Pharmacol Ther. 2013 Jan;137(1):22-54
pubmed: 22925690
Cancer Res. 2008 Jun 15;68(12):4693-700
pubmed: 18559515
Cancer Metastasis Rev. 2011 Mar;30(1):141-51
pubmed: 21298574
Oncotarget. 2017 Jul 11;8(28):46414-46424
pubmed: 28423365
PLoS One. 2019 May 31;14(5):e0217339
pubmed: 31150435
Int Immunopharmacol. 2015 Nov;29(1):93-8
pubmed: 26025503
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
CA Cancer J Clin. 2018 Jul;68(4):284-296
pubmed: 29809280
Trends Pharmacol Sci. 2008 Mar;29(3):151-8
pubmed: 18262664
Breast Cancer Res. 2005;7(6):R1186-98
pubmed: 16457699
Cell Immunol. 1996 Dec 15;174(2):116-28
pubmed: 8954611
J Clin Invest. 2007 Feb;117(2):289-96
pubmed: 17273548
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
Oncol Rep. 2017 Nov;38(5):2619-2628
pubmed: 28901507
J Ovarian Res. 2019 Mar 27;12(1):28
pubmed: 30917847
Genes Cancer. 2010 Jun;1(6):555-9
pubmed: 21779458
Cancer Genet. 2011 Oct;204(10):525-35
pubmed: 22137482
Nat Rev Genet. 2010 Oct;11(10):733-9
pubmed: 20838408
Br J Pharmacol. 2008 Aug;154(8):1558-71
pubmed: 18500366
Methods. 2003 Dec;31(4):265-73
pubmed: 14597310
Sci Rep. 2016 Jul 21;6:30129
pubmed: 27440195
Front Immunol. 2019 Apr 24;10:819
pubmed: 31068932
Clin Cancer Res. 2000 Jun;6(6):2268-78
pubmed: 10873077